Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply
- PMID: 38169498
- DOI: 10.1056/NEJMc2313228
Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply
Comment on
-
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
Similar articles
-
Enzalutamide in Biochemically Recurrent Prostate Cancer.N Engl J Med. 2024 Jan 4;390(1):90. doi: 10.1056/NEJMc2313228. N Engl J Med. 2024. PMID: 38169497 No abstract available.
-
Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.Eur Urol. 2024 Apr;85(4):397. doi: 10.1016/j.eururo.2023.11.022. Epub 2023 Dec 11. Eur Urol. 2024. PMID: 38087734 No abstract available.
-
Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed?BJU Int. 2022 Nov;130(5):580-581. doi: 10.1111/bju.15860. Epub 2022 Aug 2. BJU Int. 2022. PMID: 35879832 No abstract available.
-
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment.Expert Rev Anticancer Ther. 2024 Nov;24(11):1085-1100. doi: 10.1080/14737140.2024.2405103. Epub 2024 Sep 20. Expert Rev Anticancer Ther. 2024. PMID: 39275993 Review.
-
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.Urol Oncol. 2020 Nov;38(11):826-834. doi: 10.1016/j.urolonc.2020.03.022. Epub 2020 Jun 28. Urol Oncol. 2020. PMID: 32605736
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical